Matthew Caufield

Stock Analyst at HC Wainwright & Co.

(0)
# 5036
Out of 5,270 analysts
122
Total ratings
12.50%
Success rate
-39.03%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
Aldeyra Therapeutics
Reiterates: Buy
10 10
6.13 63.13% 11 Mar 3, 2025
4D Molecular Therape...
Reiterates: Buy
36 36
4.26 745.07% 18 Mar 3, 2025
Opthea
Reiterates: Buy
12 12
4.67 156.96% 6 Feb 28, 2025
Immunic
Reiterates: Buy
10 10
1.16 762.07% 2 Feb 21, 2025
Opus Genetics
Reiterates: Buy
8 8
0.98 716.33% 2 Feb 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
30 30
9.07 230.76% 5 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
12 12
1.15 943.48% 3 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
2 2
1.56 28.21% 15 Feb 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
32
11.25 184.44% 1 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
5 18
5.42 232.1% 6 Jan 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
30
6.75 344.44% 1 Dec 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
28 28
5.3 428.3% 7 Dec 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
30 30
4.31 596.06% 4 Nov 19, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
3 3
3.92 -23.47% 3 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
7 7
6.5 7.69% 3 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
38 38
21.54 76.42% 3 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
2 2
0.2 900% 6 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 18
n/a n/a 9 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
2 2
1.75 14.29% 5 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10
1.6 525% 4 Nov 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
28
193.17 -85.5% 1 Aug 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
n/a n/a 6 May 2, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
n/a n/a 1 Jul 18, 2022